| Date | Form | Description | Docs | XBRL | Pages |
| 04/16/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
41 | |
| 01/17/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
|
6 |
| 01/16/14 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
111 | |
| 08/27/13 | ARS | Annual report to security holders |
|
108 | |
| 01/29/13 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
244 |
| 01/30/12 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
94 |
| 02/14/11 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
102 | |
| 01/31/11 | NT 10-K | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT |
|
4 | |
| 06/29/10 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
81 | |
| 03/10/10 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
80 |
Latest News & Events
Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic
Read More...Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application
Read More...OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
Read More...